Newsmax to Join Russell 2000 and Russell 3000 Indexes

Newsmax Inc. (NYSE:NMAX) ('Newsmax' or the 'Company') today announced that the Company expects to list on the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution.
Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
'The past year has been transformational for Newsmax, and we are pleased to see our shares will soon be added to the Russell 2000® Index, one of the market's leading performance benchmarks in North America,' said Chris Ruddy, CEO of Newsmax.
Newsmax, a television and digital media company offering Americans independent news, went public on the NYSE in March.
Since then, Newsmax has made several major announcements, including expanded cable / pay TV distribution on Hulu+, putting Newsmax into top-tier penetration of around 60 million U.S. homes.
'We feel this addition of Newsmax on the Russell Index will help raise awareness and ownership of Newsmax within the institutional investment community,' continued Ruddy.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are also part of FTSE Russell, a leading global index provider.
About Newsmax
Newsmax Media, Inc. operates Newsmax, the nation's fourth highest-rated cable news network, according to Nielsen. Newsmax is carried on all major cable, satellite systems, and virtual pay TV operators. Newsmax reaches more than 40 million Americans regularly through Newsmax TV, the Newsmax+ App, its popular website Newsmax.com, and publications like Newsmax Magazine. Reuters Institute says Newsmax is one of the top 12 U.S. news brands and Forbes has called us 'a news powerhouse.'
For more information, please visit Investor Relations | Newsmax Media, Inc.
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to any changes in indications we have received from FTSE Russell regarding inclusion in certain indexes, our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled 'Risk Factors' in Newsmax's Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax's Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.
Investor Contacts
Newsmax Investor Relations
ir@newsmax.com
SOURCE: Newsmax Inc.
View the original press release on ACCESS Newswire

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

an hour ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Miami Herald

an hour ago

• Miami Herald

Trump's Iran strike could boost — or ruin — his troubled presidency

President Trump's decision to bomb Iran's nuclear sites is a high-stakes gamble that could either breathe new life into or irreparably damage his troubled second term in the White House. Yet for the world at large, it may well prove to be a welcome development. Before we get into why Trump's decision aligns with the consensus among the world's biggest democracies — that Iran should not be allowed to obtain nuclear weapons — let's remember that Trump's popularity was falling fast before the strike. Only 42% of Americans approve of Trump's job performance, while 54% disapprove of it, according to a large-sample Reuters-IPSOS poll conducted June 11-16. Most Americans view Trump negatively, not only on the economy, which was once his strong point, but also on immigration, according to polls. The U.S. economy has slowed dramatically since Trump took office and launched his erratic tariff wars. According to the latest World Bank projections, the U.S. economy will only grow by 1.4% this year, which would be half of its 2.8% growth last year, in part because of the uncertainty created by Trump's on-and-off threats to impose huge import taxes on foreign goods. Likewise, many Trump voters in states with large immigrant communities, like Florida, are disappointed by Trump's decision to deport hundreds of thousands of immigrants without criminal records, including more than 350,000 Venezuelan Temporary Protected Status (TPS) holders who entered the country legally. During the 2024 campaign, Republicans claimed that Trump would focus on deporting violent criminals. Before his Iran strike, Trump was also haunted by his growing image as a wavering leader. His repeated reversals of his own tariff ultimatums — first vowing to impose 145% tariffs on China, then reducing them to 30% — made him an object of mockery in European capitals and among U.S. critics. A Financial Times columnist popularized the acronym TACO — Trump Always Chickens out — to describe the U.S. president's trade strategy. Trump got visibly upset when he was asked about the TACO reference at a recent press conference. His fear of being perceived as an indecisive leader may have pushed him — after weeks of reportedly telling Israel's Prime Minister Benjamin Netanyahu he would not get dragged into the conflict — to join Israel's military offensive against Iran's nuclear sites. But if Trump's Iran gamble turns out well and Iran's theocratic dictatorship either crumbles or gives up its uranium enrichment program through diplomatic negotiations — a big if — Trump will be credited with having done something four previous presidents contemplated but ultimately failed to do. Internationally, virtually all major Western democracies agrees that Iran is a threat to Israel, and to the world. In a statement at the end of the June 16 summit of the G-7 group of Western democracies in Alberta, Canada, the leaders of the United States, the United Kingdom, France, Germany, Japan, Italy and Canada said that 'We have been consistently clear that Iran can never have a nuclear weapon.' The G-7 bloc's statement added that 'Iran is the principal source of regional instability and terror in the Middle East,' and that 'We affirm that Israel has a right to defend itself.' Days earlier, on June 12, the International Atomic Energy Agency (IAEA) for the first time in 20 years issued a statement warning that Iran was not complying with its nuclear nonproliferation agreements. Translation: Iran was enriching uranium at levels only justified to build nuclear weapons. Skeptics who don't follow Iran's political history may ask themselves why the world doesn't allow Iran to have nuclear weapons like India, Pakistan and other countries. The answer is simple: Unlike other countries, Iran has a state policy of trying to 'eliminate' a nearby sovereign country — Israel— that has been recognized by the United Nations since 1948. This is not about Western countries being against Iran's Jurassic theocracy for imprisoning women for failing to cover their heads with a hijab, or for executing gays, or any of its other abhorrent internal policies. The reason is that if we allow a country that calls for the destruction of another nation to have a nuclear bomb, it will set a precedent that makes the world even more dangerous. In Iran's case, it's not just Iranian Supreme Leader Ayatollah Ali Khamenei's crazy rhetoric, but his actions. Iran has long provided financial aid to terrorist groups like Hezbollah in Lebanon and Hamas in Gaza. Iran's proxies have carried out terrorist attacks as far away as Argentina, where Hezbollah was found responsible for the bombing that killed 85 people and wounded hundreds at the AMIA Jewish Community Center in Buenos Aires in 1994. There are many ways in which Trump's political gamble may go wrong, especially if Iran moved some of its enriched uranium into a secret location outside Fordo, or if it unifies Iranians behind their decrepit regime. But if Iran's regime falls, or agrees to a serious international nuclear monitoring agreement, Trump's faltering second term will get a second wind. Don't miss the 'Oppenheimer Presenta' TV show on Sundays at 9 pm E.T. on CNN en Español. Blog:

Business Insider

2 hours ago

• Business Insider

‘Still Not a Bargain,' Says Top Investor About Nike Stock

'Just Do It,' goes the motto that Nike (NYSE:NKE) made a household catchphrase. With its branded 'Swoosh' and world-famous spokespeople, it is no stretch to argue that Nike helped to build the premium shoe market — one that grew by leaps and bounds earlier this decade. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Indeed, the COVID years saw a major spike in Nike's footwear sales – from $23.3 billion in 2020 to over $35 billion in 2023 – though growth has been slowing of late. Last year saw footwear revenues decrease slightly, and its share price has fallen almost 40% during the past twelve months. This week, Nike will be releasing its FQ4 2025 results, and consensus estimates are not exactly bullish. Analysts are expecting total revenues of $10.7 billion – down 15% year-over-year – while a projected EPS of $0.12 would represent an 89% decrease year-over-year. One top investor known by the pseudonym Stone Fox Capital thinks that the growing competition will continue to present stiff resistance going forward. 'Nike remains overvalued despite a significant price decline, with the market underestimating downside risks and ongoing competitive pressures,' explains the 5-star investor, who is among the top 3% of TipRanks' stock pros. The biggest challenge for Nike going forward will be the growing competition, asserts Stone Fox Capital, citing On Holding and HOKA as two of the biggest threats. For instance, ONON's On Running is expected to grow revenues by 40% this year. Still, NKE is trading 'at multiples above the market,' despite forecasts of stagnating growth going forward. Stone Fox Capital spots quite a disconnect – one that the market has yet to take fully into account. 'Nike should be viewed based on the readily available data of a massive athletic footwear company that hasn't grown in years facing immense competition,' adds Stone Fox Capital. Stone Fox Capital is urging investors to pay attention to upcoming guidance for the next quarter, which the investor predicts will be a 'horrible' forecast. Needless to say, Stone Fox Capital does not believe that 'Just Do It' is good advice for would-be investors at present. 'The stock might be down substantially from the all-time highs a few years ago, but Nike isn't actually trading like the business is under pressure,' concludes Stone Fox Capital, who rates NKE a Sell. (To watch Stone Fox Capital's track record, click here) Wall Street is overall positive when it comes to Nike, though not overwhelmingly. With 12 Buy and 11 Hold ratings, NKE is a consensus Moderate Buy. Its 12-month average price target of $71.24 has an upside of ~19%. (See NKE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.